Working... Menu

Feasibility of iFS™ for Intrastromal Arcuate Keratotomy (ISAK) Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01210820
Recruitment Status : Completed
First Posted : September 29, 2010
Results First Posted : April 26, 2013
Last Update Posted : May 1, 2013
Information provided by (Responsible Party):
Abbott Medical Optics

Brief Summary:
The results of this trial will demonstrate that ISAK performed with the iFS™ femtosecond laser is a safe procedure.

Condition or disease Intervention/treatment Phase
Refractive Astigmatism Device: iFS™ Femtosecond Laser System Not Applicable

Detailed Description:
Surgeon will perform intrastromal arcuate keratotomy in arc segment patterns using the iFS™ femtosecond laser to treat subjects with refractive astigmatism.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Single Center Study To Evaluate the Feasibility of Intrastromal Arcuate Keratotomy Performed With the IntraLase iFS™ Femtosecond Laser System
Study Start Date : July 2010
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Arm Intervention/treatment
Experimental: Natural Astigmatism
Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
Device: iFS™ Femtosecond Laser System
intrastromal arcuate cuts made with iFS™ femtosecond laser
Other Name: iFS™ is part of the product brand name - there is no expanded acronym

Experimental: Post cataract with residual astigmatism
Subjects who have had cataract removal surgery but have residual astigmatism.
Device: iFS™ Femtosecond Laser System
intrastromal arcuate cuts made with iFS™ femtosecond laser
Other Name: iFS™ is part of the product brand name - there is no expanded acronym

Primary Outcome Measures :
  1. Change in Refractive Astigmatism [ Time Frame: 6 months ]
    Change in mean cylinder (assessed by manifest refraction) compared to baseline.

  2. Change in Keratometric Cylinder [ Time Frame: 6 Months ]
    Change in mean keratometric cylinder (as measured by keratometry) compared to baseline.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, of any race, and at least 21 years of age at the time of the pre-operative examination and signing the consent form
  2. Refractive error, no limitation on spherical refractive myopia or hyperopia and refractive astigmatism of 0.75 to 7.00 diopters (D) in the operative eye
  3. Best Spectacle Corrected Distance Visual Acuity (BSCVA)

    • Group 1: Natural astigmatism, no cataract: BSCVA of 20/25 or better in both eyes
    • Group 1: Pre cataract surgery, no BSCVA criteria in the operative eye
    • Group 2: Post cataract surgery, BSCVA of 20/25 or better in both eyes
  4. Uncorrected Visual Acuity (UCVA) of 20/40 or worse in the operative eye
  5. Demonstration of agreement in the operative eye: Corneal astigmatism (as determined by keratometry) must be in agreement with refractive astigmatism (as determined by manifest refractions) as follows: Within ≤ 0.75 D in magnitude and within 15° axis when cylinder ≤ 1.5 D or 10° axis when cylinder > 1.5 D.
  6. Preoperative central and peripheral (in planned treatment area) pachymetry of ≥ 500 um in the operative eye
  7. Keratometry must be between 38.0 (flat) and 48.0 D (steep) in the operative eye
  8. Corneal power (diopters) difference at the 3mm point from topographic center shall be ≤ 1D at the steepest meridian, by topography measurements in the operative eye
  9. Intraocular pressure (IOP) of 12 to 21 mm Hg in the operative eye with no glaucomatous retinal changes
  10. Stable refractive error in the operative eye, based on an exam (or prescription) at least 6 months prior to the pre-operative examination, and as compared to the pre-operative manifest refraction, must be ≤ 0.75 D (sphere and cylinder) and axis within 15 degrees for eyes with cylinder > 0.5D.
  11. Subjects who have worn a contact lens in the operative eye within the past 30 days must remove the soft lens at least 2 weeks prior and a rigid or toric lens at least 3 weeks prior to baseline measurements. In addition, rigid or toric lens wearers must demonstrate stability in topography, keratometry and refraction before proceeding with surgery. Refractive stability is defined as a change of not more than 0.50 D in manifest sphere, cylinder, or keratometry (either axis) as compared to the unadjusted preoperative refraction in two visits at least one week apart.
  12. Willing and capable of returning for follow-up examinations for the duration of the study
  13. Subject must sign and be given a copy of the written Informed Consent Form

Exclusion Criteria:

  1. Abnormal topography, including evidence of keratoconus or pellucid marginal degeneration, in either eye
  2. Irregular astigmatism in the operative eye
  3. Evidence of clinically significant corneal opacity/scar in the operative eye within an 8 mm diameter zone of the visual axis
  4. Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study, as determined by verbal inquiry
  5. Concurrent use of topical or systemic medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment
  6. History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis
  7. History of active ophthalmic disease or other non-refractive abnormality (including, but not limited to, corneal dystrophy, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), retinal detachment/repair, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma NOTE: Subjects with open angle glaucoma, regardless of medication regimen or control, or an IOP greater than 21 mm Hg at baseline, are specifically excluded from eligibility.
  8. Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course
  9. Participation in any other conflicting ophthalmic drug or device clinical study during the period of participation in this clinical investigation -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01210820

Layout table for location information
Paracelsus Medizinische Privat-Universitat, PMU
Salzburg, Austria, 5020
Sponsors and Collaborators
Abbott Medical Optics
Layout table for investigator information
Study Director: Nicholas Tarantino, OD Abbott Medical Optics

Layout table for additonal information
Responsible Party: Abbott Medical Optics Identifier: NCT01210820     History of Changes
Other Study ID Numbers: FMTO-102-ISAK
First Posted: September 29, 2010    Key Record Dates
Results First Posted: April 26, 2013
Last Update Posted: May 1, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases